ArticleEULAR rheumatology open2026
Assessing the real-world impact of interstitial lung disease in patients with rheumatoid arthritis on healthcare resources and treatment patterns through natural language processing.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From electronic health records to real-world evidence: Savana Next-Generation Registry digital solution.ESMO real world data and digital oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Interstitial lung disease (ILD) is a serious pulmonary complication and a major cause of morbidity and mortality in several connective tissue diseases, notably rheumatoid arthritis (RA). We developed a study to compare the healthcare resource utilisation in patients with RAILD and RA-non-ILD and establish the impact of ILD diagnosis in the treatment of patients with RA using natural language processing (NLP) of electronic health records (EHRs). Methods: This observational, retrospective, multicentre study analysed unstructured clinical data from EHRs of patients with RA with and without ILD (RAILD and RA-non-ILD) from 9 hospitals in Spain, spanning January 2014 to December 2019. NLP was used to extract and standardise data into Systematized Nomenclature of Medicine - Clinical Terms (SNOMED-CT) terminology. The study aimed to compare healthcare resource utilisation and treatment patterns between the 2 groups, focusing on changes in treatment following ILD diagnosis in patients with RAILD. Results: Among 13,958 patients with RA, 712 (5.1%) were identified as having RA-ILD, with 433 diagnosed during the study period. Patients with RAILD had significantly higher healthcare resource utilisation than patients with RA-non-ILD, particularly in pneumology (60.5% vs 9.0%), internal medicine (37.4% vs 19.9%), and emergency departments (57.3% vs 39.1%). Hospitalisation rates were also higher in patients with RAILD (64.5% vs 31.9%). Prior to ILD diagnosis, tumour necrosis factor inhibitors were the most commonly prescribed treatments, whereas after diagnosis, drugs with different mechanisms, such as rituximab and abatacept, were more frequently initiated. Conclusions: The development of ILD in patients with RA is associated with increased healthcare resource utilisation and different treatment patterns. NLP on EHRs is a valuable tool for offering insights into disease management and healthcare burden in patients with RAILD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.